Related Experiment Videos
Cytogenetic testing for therapeutic indication in cancer
Suneel Mundle1, Yelina Noskina
1Rush University Medical Center, Department of Biochemistry, Naperville, Chicago, IL 60565, USA. smundle@rush.edu
Expert Review of Molecular Diagnostics
|February 23, 2005
Summary
Cytogenetic abnormalities are linked to cancer, but new molecular diagnostics reveal their potential as therapeutic targets. This shift offers hope for targeted cancer treatments, moving beyond just diagnosis and prognosis.
Area of Science:
- Oncology
- Genetics
- Molecular Diagnostics
Background:
- Cytogenetic abnormalities are historically recognized as diagnostic and prognostic cancer indicators.
- Limited understanding of their functional roles has historically prevented their use as therapeutic targets.
Purpose of the Study:
- To review the role of molecular diagnostics in advancing the understanding of cytogenetic abnormalities.
- To explore the potential of specific cytogenetic alterations as therapeutic targets in cancer treatment.
Main Methods:
- Review of recent developments in chronic myelogenous leukemia and breast cancer research.
- Analysis of the contribution of molecular diagnostics to identifying therapeutic targets.
Main Results:
- Recent advancements highlight specific cytogenetic alterations as promising therapeutic targets.
- Molecular diagnostics are crucial in uncovering the functional significance of these abnormalities.
Conclusions:
- Cytogenetic abnormalities are transitioning from mere indicators to actionable therapeutic targets.
- Molecular diagnostics are pivotal in realizing the therapeutic potential of cancer-related genetic alterations.